Articles tagged with Clinical Trials
A clinical trial led by Mount Sinai researchers shows zodasiran, an RNA inhibitor targeting ANGPTL3, significantly reduces various types of cholesterol and triglycerides. The therapy also lowers apolipoprotein B, a lipid-transporting protein linked to heart disease.
Researchers from Ben-Gurion University of the Negev have discovered a link between proteomic biomarkers and liver fat percentage, which may improve patient monitoring and therapy targeting for NAFLD. The study, conducted over 18 months, found that specific protein changes were independently associated with liver fat relative change.
The SELECT Trial found semaglutide to significantly reduce the risk of kidney-related complications and improve kidney function in individuals with overweight or obesity and cardiovascular disease. The study revealed that semaglutide's ability to prevent macroalbuminuria was a key factor in reducing kidney-related events.
A groundbreaking study reveals semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease. Semaglutide also shows improved safety and efficacy profiles.
SWOG Cancer Research Network will share results of their work in 30 presentations at the 2024 American Society of Clinical Oncology Annual Meeting, May 31 – June 4 in Chicago. The research focuses on improving cancer treatments and reducing devastating side effects.
Researchers from Penn Medicine's Abramson Cancer Center and Perelman School of Medicine will present results from clinical trials for esophageal cancer, CAR T cell therapy, and ovarian cancer. The meeting will feature more than 200 sessions on AI in cancer care.
A cluster randomized trial found that at-school HPV vaccination significantly increased vaccination coverage, but training general practitioners and education had limited impact. The study aimed to assess the effectiveness of a school- and primary care-based HPV vaccination intervention.
A new study at the University of Copenhagen reveals that urolithin A, a naturally occurring substance in pomegranates, can alleviate memory problems and other consequences of dementia. The substance shows promise in improving brain function by removing damaged mitochondria.
The FDA committee voted unanimously to approve minimal residual disease (MRD) as a new clinical endpoint for evaluating proposed drugs to treat multiple myeloma. A meta-analysis led by C. Ola Landgren shows a strong correlation between MRD and clinical outcomes in newly diagnosed and relapsed patients.
The conference will feature 12 late-breaking clinical trials and science presentations on transcatheter aortic valve replacement, mitral and tricuspid devices and techniques. Data from these trials will guide the selection of patients who will benefit most from procedures and define optimal treatment strategies.
Researchers found no significant 'participation effect' in cancer trials, contrary to common belief among patients and healthcare providers. The study's results provide reassurance that not enrolling in a trial doesn't disadvantage a patient's survival outcomes.
Researchers report that dupilumab substantially decreases exacerbation frequency and improves lung function as well as symptom burden in COPD patients with type 2 inflammation. The study's findings are promising for these patients, who have a high risk of exacerbations.
A new study at Hebrew University found that guided internet-based cognitive behavioral therapy significantly improves depression and insomnia symptoms over time. The study emphasizes the importance of the therapeutic alliance and attachment styles in predicting treatment outcomes.
Research found that race-neutral spirometry equations tend to decrease severity for white patients and increase severity for Black patients, leading to higher enrollment rates of Black patients in COPD clinical trials. This shift resulted in more Black subjects meeting typical inclusion criteria, while fewer white subjects were eligible.
A phase 3 trial found that pamrevlumab did not significantly improve lung function in patients with idiopathic pulmonary fibrosis. The study's results underscore the need for effective treatments to slow disease progression and improve patient outcomes.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
A web-based cognitive behavioral self-help intervention has been shown to effectively reduce binge eating episodes and improve various mental health outcomes in patients with binge eating disorder. This scalable solution bridges the treatment gap for this condition, offering a promising alternative to traditional therapies.
A study published in Circulation found that revascularization significantly enhances the health-related quality of life (HRQoL) for patients with chronic limb-threatening ischemia. Patients who underwent endovascular intervention (Endo) showed slight statistical superiority over those who received surgical bypass (Bypass) in some HRQoL...
Scientists have recruited over 20,000 volunteers to a resource aimed at accelerating dementia drug development. The cohort will enable healthy individuals with increased genetic risk to participate in clinical trials, allowing researchers to test new treatments before symptoms appear.
A clinical trial found that aficamten significantly increased maximum oxygen use in patients with obstructive hypertrophic cardiomyopathy. This improvement enables patients to perform everyday tasks more easily, such as walking and household chores. Researchers believe aficamten has promise as a treatment for this condition.
A secondary analysis of a randomized clinical trial found that home blood pressure self-monitoring plus medication self-titration reduces BP in the longer term without increasing healthcare use or adverse events. This simple, inexpensive intervention has potential to improve long-term hypertension control in routine clinical practice.
Researchers at the University of Oklahoma are developing evidence-based mobile health interventions to treat substance use disorders. By leveraging smartphones, they aim to create highly tailored interventions delivered at the right time for individuals, reducing stigma and improving treatment outcomes.
A clinical trial found that adding Radix Salviae decoction to conventional treatment did not change coronary stenosis and restenosis rates after percutaneous coronary intervention. The diagnosis of MI/angina, average stent length, and ALT levels were associated with neostenosis occurrence.
A third Covid vaccine dose has been shown to improve defensive antibody responses in some clinically extremely vulnerable patients. The trial found that 90% of patients who received a booster dose developed significant antibodies, but more than half of those with low initial responses saw no improvement.
A new Cochrane review suggests that taking zinc may reduce the duration of common cold symptoms by around two days, but the evidence is not conclusive. Common side-effects include bowel problems, nausea, and unpleasant taste.
Researchers at UCSF used an AI model to analyze clinical notes and determine patient urgency, achieving an accuracy rate of 89% and surpassing human physician performance in 88% of cases. The study suggests AI could help alleviate ED overcrowding by providing backup decision-making tools for clinicians.
Substantial geographic disparities in cancer clinical trials availability exist in the US, with socially vulnerable counties facing significant limitations. The disparity has worsened over time, with these counties often having fewer trial options available.
A phase 1/2 trial of CRISPR gene editing has demonstrated safety and efficacy, with measurable improvements in 11 out of 14 participants with a form of inherited blindness. The treatment, EDIT-101, was found to be clinically meaningful for four participants and showed significant improvements in cone-mediated vision.
Jeffrey W. Moses, MD, is recognized for advancing the field of interventional cardiovascular medicine through technical excellence and leadership. Dr. Moses has performed over 20,000 interventional procedures and made significant contributions to clinical research and educational activities in interventional vascular therapy.
A head-mounted device generating an ultra-low frequency magnetic field has improved symptoms of four male patients with major depressive disorder. The study suggests that future trials may offer a safe and non-invasive way to treat depression.
A pioneering CRISPR gene editing trial has demonstrated significant improvement in vision for 79% of participants with inherited retinal degeneration. The study's findings support further research into the potential of CRISPR-based treatments for inherited blindness.
A clinical trial shows that cytisinicline can help people quit vaping by reducing the likelihood of relapse and improving behavioral support. The study found that participants taking cytisinicline were more than twice as likely to abstain from vaping for weeks 9-12 compared to those receiving a placebo.
The PSMAfore study found that 177Lu-PSMA-617 prolonged radiographic progression-free survival and improved PSA response rate compared to a change in ARPI. Treatment with 177Lu-PSMA-617 also increased objective response rate, regardless of prior treatment.
European clinical trials suggest that dequalinium chloride (DQC) may be a viable and well-tolerated treatment option for bacterial vaginosis, but more robust US studies are needed to confirm its effectiveness. The existing BV treatments in the US have limited success, with high recurrence rates after antibiotic therapy.
A new mRNA cancer vaccine has been shown to trigger a vigorous immune response in both human patients and pet dogs with glioblastoma, the most aggressive form of brain cancer. The breakthrough treatment, which uses a personalized approach and novel delivery mechanism, demonstrates promising results in early clinical trials.
Researchers found that metformin decreases the amount of COVID-19 virus in the body and lowers the chances of viral rebound. The study showed a significant reduction in long COVID cases and hospitalizations among adults treated with metformin.
Menopausal hormone therapy is appropriate to treat vasomotor symptoms in early menopause without contraindications. WHI evidence does not support routine supplementation with calcium plus vitamin D or a low-fat diet for preventing fractures and breast/colorectal cancer, respectively.
Researchers designed a new AI model that accurately predicts treatment outcomes for stroke prevention in people with heart disease. The model, called CURE, was trained on a massive dataset of de-identified patient information and fine-tuned to focus on specific health conditions and treatments.
The study, led by Marshall University Joan C. Edwards School of Medicine, aims to determine if fertilized ACL surgery enables athletes to return to play sooner. Patients will undergo various tests and assessments before, during, and after surgery.
A systematic review and meta-analysis found no association between new-onset seizures and SARS-CoV-2 vaccination. The study included over 118,000 participants from randomized clinical trials and found the incidence proportion of new-onset seizures to be similar across vaccine recipients and unvaccinated participants.
A commentary highlights the importance of including nursing home residents in clinical trials to address health equity concerns. The authors propose key elements for successful nursing home clinical trials and emphasize the benefits of conducting research in this setting.
Robert A. Harrington, MD, will be honored for his groundbreaking work in clinical research and clinical excellence. He has made extraordinary contributions to the field of interventional cardiology, transforming cardiovascular care through his pioneering research and mentorship.
A randomized clinical trial of 3,020 patients with high-risk nonmetastatic breast cancer found daily aspirin therapy had no effect on breast cancer recurrence or survival in early follow-up. Aspirin should not be recommended as an adjuvant breast cancer treatment despite its potential benefits and wide availability
A phase 1/2 trial found microarray patches to be safe and induce strong immune responses in children, with over 90% protected from measles. The method could help achieve high population immunity levels required to control childhood diseases.
Administration of antenatal corticosteroids to late preterm babies was not linked to increased risk of neurodevelopmental problems by age 6. Long-term follow-up study suggests the medication may be safe for these high-risk infants.
A phase 3 clinical trial found that 96.7% of patients did not experience severe vaso-occlusive crises, and all remained hospitalization-free for at least one year after receiving the gene therapy CASGEVY.
Researchers at Baylor College of Medicine conducted a phase I clinical trial using CAR T cells engineered to target the HER2 protein, which is overexpressed on sarcoma cells. The therapy showed safety and associated with clinical benefit, with improved CAR T expansion and persistence.
The Alzheimer's disease treatment landscape is experiencing a significant shift, with numerous potential drugs making their way through clinical trials. Biomarkers have also emerged as a key area of focus, providing valuable information on the drug's impact and allowing for more precise guidance in future trials.
The FDA has approved the use of N-803, an immunotherapy drug, in combination with BCG for treating patients with non-muscle invasive bladder cancer who did not respond to conventional treatment. The approval is based on a trial led by UCLA's Dr. Karim Chamie, which showed improved outcomes and longer overall survival rates.
A randomized clinical trial found self-administered acupressure to be efficacious and cost-effective in reducing knee pain and improving mobility in middle-aged and older adults with probable osteoarthritis. The treatment also showed significant benefits in terms of quality of life.
A phase 3 trial shows that pembrolizumab significantly prolongs overall survival in high-risk kidney cancer patients. The treatment delays recurrences and helps patients live longer, with a 38% reduction in risk of death compared to placebo.
Researchers found that individuals from certain racial and ethnic groups are less likely to be eligible for Alzheimer's disease clinical trials due to lower amyloid levels at early stages of the disease. Amyloid buildup in the brain varies across different populations, contributing to underrepresentation in clinical trials.
The phase 2 study found an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a significant improvement over the baseline annualized growth velocity. The treatment was well-tolerated, and some patients showed excellent responses to vosoritide.
Researchers found that riociguat significantly improved blood pressure and reduced the risk of serious adverse events compared to a placebo treatment. The study showed promising results for this potential new treatment to manage complications from sickle cell disease, paving the way for larger clinical trials.
Researchers analyzed blood stem cells in mice with prior sepsis and found they were fully recovered but failed to respond to a second inflammatory stimulus, leading to inefficient immune cell production.
A new three-step prostate cancer screening method can detect aggressive cancers while minimizing the detection of insignificant ones. The study found that this approach reduces unnecessary diagnoses and may lead to improved mortality rates.
A study from the University of Gothenburg found that patient images are severely lacking in scientific articles on atopic dermatitis. This lack of visual aids hinders patients' ability to make informed decisions about their care, as they struggle to understand complex medical terminology and figures. The absence of images also affects ...
A phase I trial demonstrated AZD1390's manageable safety profile and preliminary efficacy in recurrent and newly diagnosed glioblastoma patients. The study showed improved overall survival, with a median of 12.7 months in patients who received higher doses of AZD1390.
A clinical trial found that a nasal spray called etripamil effectively and safely treated recurrent episodes of paroxysmal supraventricular tachycardia (PSVT) in patients. The study showed that two-thirds of participants experienced relief within an hour, with an average time needed for symptom relief being 17 minutes.
A 10-minute virtual reality session significantly lessened pain in hospitalized patients with cancer, with sustained benefits even a day later. The study found that VR sessions had a greater impact than guided imagery, improving not only pain severity but also related issues like general distress.